精確搜索結(jié)果
- Products
- 內(nèi)容類型
- Analysis Platform
- 語言
- Publication Date
1 - 20 共 25 條結(jié)果
應(yīng)用的篩選條件
基于實(shí)時(shí)細(xì)胞分析的藥物毒理學(xué)研究與心臟安全性評價(jià)
本應(yīng)用簡報(bào)為使用 XF 線粒體毒性檢測進(jìn)行化合物篩選和劑量響應(yīng)實(shí)驗(yàn)以及使用線粒 體毒性指標(biāo) (MTI) 解析結(jié)果數(shù)據(jù)提供了概念驗(yàn)證和示例。
| 英語 (美國) | 完整版（PDF） |
|---|
了解用于評估線粒體毒性的安捷倫 Seahorse XF 線粒體毒性測定解決方案的原理和參數(shù)計(jì)算
| 英語 (美國) | 完整版（PDF） |
|---|
本應(yīng)用簡報(bào)介紹了一種由阿爾伯達(dá)毒理學(xué)中心開發(fā)的，用于水源監(jiān)測的無標(biāo)記實(shí)時(shí)細(xì)胞分析方法。這種體外細(xì)胞毒性分析使用基于阻抗的 Agilent xCELLigence 實(shí)時(shí)細(xì)胞分析儀 (RTCA)。該方法可以無創(chuàng)地連續(xù)監(jiān)測水樣中存在的累積毒性物質(zhì)對細(xì)胞生長的干擾。分析中通過水毒性指數(shù) (WTI)、生物效應(yīng)...
| 英語 (美國) | 完整版（PDF） |
|---|
最近的發(fā)現(xiàn)已經(jīng)將線粒體功能障礙和細(xì)胞生物能量缺陷與包括肥胖、糖尿病、癌癥、心肌癥和神經(jīng)退行性疾病在內(nèi)的許多疾病的病理生理學(xué)聯(lián)系起來。細(xì)胞外通量 (XF) 技術(shù)的推出使活細(xì)胞中細(xì)胞生物能量和線粒體功能的無創(chuàng)、實(shí)時(shí)分析成為可能，為研究這些疾病提供了一種新的手段。
那些可以保護(hù)儲備容量不受損失，或者誘導(dǎo)線粒體生物發(fā)生的藥物被認(rèn)為有可能治療多種病狀。我們采用近曲腎小管上皮細(xì)胞的原代培養(yǎng)物，并且使用 XF96 分析儀實(shí)時(shí)測量線粒體的呼吸作用，這些近曲腎小管上皮細(xì)胞表現(xiàn)出體內(nèi)水平的有氧代謝，而非糖酵解，并且保留有較高水平的分化功能。
安捷倫 Seahorse XF 分析儀可實(shí)時(shí)同步測定活細(xì)胞中的兩種主要細(xì)胞能量代謝途徑，即線粒體呼吸和糖酵解。Seahorse XF 分析儀適用于所有細(xì)胞類型，包括原代細(xì)胞、細(xì)胞系、懸浮細(xì)胞、胰島、秀麗隱桿線蟲、酵母和分離的線粒體。
安捷倫 Seahorse XF 分析儀采用專利瞬態(tài)微室，可進(jìn)行靈敏、精確且無損的實(shí)時(shí)代謝測量。
使用安捷倫 Seahorse XFe 分析儀和 Bravo 自動(dòng)化液體處理平臺演示線粒體抑制劑的劑量響應(yīng)研究。
The invasion of the 3D spheroid in the presence or absence of drug treatment was monitored and quantified using the brightfield and fluorescence live cell time-lapse
Specification data sheet for the Agilent xCELLigence Real-Time Cell Analyzer HT-Biotek BioSpa 8.
A protocol for mitocondrial isolation and oxygen consumption analysis using the Agilent MitoXpress Xtra oxygen consumption assay.
ASMS 2023 Poster - This poster shows ver 200 pesticides screened for, using a DIA mode of acquisition from 0.625 ppb to 100 ppb? using the new Agilent Revident LC/Q-TOF? showing good Mass Accuracy, Low RSD’s, Scored Coelution of Fragment Ions?.
ASMS 2023 Poster - An Agilent Captiva EMR—Lipid pass-through cleanup for PAH analysis in infant formula and the use of the Agilent HydroInert source with H2 carrier gas on the Agilent 8890 GC and 5977C GC/MSD system can be used for the determination...
In this webinar, Julie Eakins, Senior Research Scientist at ADME-Tox Specialists Cyprotex, will discuss a number of in vitro approaches to detect compounds which can result in mitochondrial toxicity. Using a combination of different assays on the...
Presentation by Daniel Gebhard at the 4th German Pharma Tox Summit, Stuttgart, Germany, discussing workflows and case study examples of direct, real-time measurement of mitochondrial toxicity.
A demonstration of combining microelectrode-based iPS cardiomyocyte contractility measurements with microplate-based bioenergetics assessment to characterize cellular responses to drug treatment.
Two Workflows: A Streamlined 384-well workflow to detect direct drug-induced mitochondrial dysfunction and Multiplexed workflow to detect mitochondrial toxicity after longer treatments
Examines the phosphorylation of signal transducer and activator of transcription (STAT) proteins in response to cytokine stimulation using a phosphoflow technique.
A demonstration of the performance of the Agilent MitoXpress Xtra oxygen consumption assay for identifying drug induced mitocondrial toxicity.